LIDDS to evaluate a possible listing of the company's shares on Nasdaq Stockholm's Main Market during 2020

STOCKHOLM - Lidds (Nasdaq First North: LIDDS) announced today that the company will evaluate a possible listing of its shares on Nasdaq Stockholm's Main Market during 2020 and will engage advisors to explore this potential relisting.

LIDDS is in a strong growth and expansion phase with several key projects in clinical and pre-clinical phases, including the Phase IIb Liproca® Depot study, the Phase I NanoZolid®-docetaxel study and preclinical programs in immuno-oncology.

A transition from Nasdaq First North to Nasdaq Stockholm's Main Market can increase LIDDS' visibility both for partnering and from a capital markets perspective.

-We see a listing on Nasdaq Stockholm's Main Market as a natural next step in the company's development. A move to Nasdaq Stockholm's main market can contribute to increased interest from a broader investor base while at the same time increasing visibility for partners, both in Sweden and globally, says Monica Wallter, CEO, LIDDS.

-It is clear that our shareholder base has developed significantly in recent years, both in terms of number of shareholders that we have as well as now having larger and longer-term institutional and private investors, says Jan Törnell, Chairman of the Board of LIDDS.

-It is logical now to evaluate a listing on the main market while continuing this development, says Jan Törnell.

For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 070 922, monica.wallter@liddspharma.com

LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation. The information was submitted through the agency of the aforementioned contact person for publication on
18 March 2019 at 08.45 CET.
                 
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com